Table 2.
Clinical and laboratory findings in patients with PI and PS.
| Case | Age | Gender | PI | PS | β2-GPIaCL | ANA | Type of |
|---|---|---|---|---|---|---|---|
| (y) | stroke | ||||||
| 1 | 68 | Male | 0.5 | 1.4 | (−) | D80× | L |
| 2 | 63 | Male | 1.1 | 1 | (−) | D80× | C |
| 3 | 72 | Male | 2.1 | 0.6 | (−) | (−) | L |
| 4 | 58 | Male | 1.9 | 1.7 | (−) | D80× | A |
| 5 | 64 | Female | 1.6 | 1.5 | (−) | D80× | L |
| 6 | 78 | Male | 0.8 | 1.3 | (−) | D40× | L |
| 7 | 48. | Female | 1.9 | 1.5 | (−) | D640× | L |
| 8 | 66 | Male | 1 | 0.5 | (−) | (−) | L |
| 9 | 43 | Male | 1.8 | 0.7 | (−) | N160× | A |
| 10 | 71 | Male | 1.1 | 1 | (−) | SP40× | L |
| 11 | 70 | Male | 1.9 | 0.8 | (−) | D80× | A |
| 12 | 60 | Male | 1.4 | 1.1 | (−) | D40× | A |
| 13 | 64 | Male | 1.1 | 0.9 | (−) | SP40× | L |
| 14 | 49 | Male | 2.1 | 0.9 | (−) LA + | (−) | A |
| 15 | 58 | Male | 1.5 | 1.4 | (−) | D+N40× | A |
| 16 | 68 | Female | 1.5 | 1.2 | (−) | D160× | L |
| 17 | 53 | Female | 8.1 | 1.1 | (−) | SP N80× | A |
| 18 | 72 | Female | 1.5 | 1 | (−) | SP80× | L |
| 19 | 71 | Male | 1 | 0.7 | (−) | (−) | L |
| 20 | 73 | Female | 1.3 | 0.8 | (−) | SP80× | L |
| 21 | 64. | Female | 1.1 | 1.3 | (−) | D640× | A |
| 22 | 81 | Male | 1 | 0.9 | (−) | SP40× | L |
| 23 | 76. | Male | 1.3 | 1.6 | (−) | SP40× | A |
| 24 | 80 | Male | 1 | 1.3 | (−) | D80× | A |
| 25 | 83 | Female | 0.7 | 1.4 | (−) | (−) | A |
| 26 | 44 | Male | 2.1 | 1.3 | (−) | D2560× | C |
| 27 | 52. | Male | 2.1 | 2.9 | (−) | SP40× | A |
| 28 | 79 | Male | 0.7 | 1.1 | (−) | (−) | L |
| 29 | 76 | Female | 0.8 | 1.1 | (−) | D80× | L |
| 30 | 65 | Male | 0.8 | 1.1 | (−) | SP40× | L |
| 31 | 63. | Female | 0.5 | 1.8 | (−) | SP40× | C |
| 32 | 31 | Male | 1.4 | 1.3 | (+) LA + | D320× | A |
| 33 | 50 | Male | 0.5 | 1.1 | (+) LA + | (−) | A |
| 34 | 46 | Female | 5.2 | 7.6 | (−) | SP80× | A |
L: lacunar infarction, A: atherothrombotic infarction, C: cardiogenic embolism D: diffuse pattern, SP: speckled pattern, and N: nucleolar pattern.